메뉴 건너뛰기




Volumn 21, Issue 4, 2008, Pages 215-217

Drug therapy in liver diseases

Author keywords

Cirrhosis; Drugs; Farmacodynamics; Pharmacokinetics

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA LACTAM ANTIBIOTIC; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERFERON; ISONIAZID; LORAZEPAM; METHOTREXATE; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PEFLOXACIN;

EID: 67651109110     PISSN: 11087471     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial
Times cited : (4)

References (19)
  • 1
    • 13244297157 scopus 로고    scopus 로고
    • The hepatic sinusoid in aging and cirrhosis: Effects on hepatic substrate disposition and drug clearance
    • Le Couteur DG, Fraser R, Hilmer S, Rivory LP, McLean AJ. The hepatic sinusoid in aging and cirrhosis: effects on hepatic substrate disposition and drug clearance. Clin Pharmacokinet 2005;44:187-200.
    • (2005) Clin Pharmacokinet , vol.44 , pp. 187-200
    • Le Couteur, D.G.1    Fraser, R.2    Hilmer, S.3    Rivory, L.P.4    McLean, A.J.5
  • 2
    • 0032937925 scopus 로고    scopus 로고
    • Glucuronidation of drugs by hepatic microsomes derived from healthy and cirrhotic human livers
    • Furlan V, Demirdjian S, Bourdon O et al. Glucuronidation of drugs by hepatic microsomes derived from healthy and cirrhotic human livers. J Pharmacol Exp Ther 1999;289:1169-1175.
    • (1999) J Pharmacol Exp Ther , vol.289 , pp. 1169-1175
    • Furlan, V.1    Demirdjian, S.2    Bourdon, O.3
  • 4
    • 1942421303 scopus 로고    scopus 로고
    • The effect of liver cirrhosis on the regulation and expression of drug metabolising enzymes
    • Elbekai RH, Korashy HM, El-kadi OS. The effect of liver cirrhosis on the regulation and expression of drug metabolising enzymes. Curr Drug Metab 2000; 5:157-167.
    • (2000) Curr Drug Metab , vol.5 , pp. 157-167
    • Elbekai, R.H.1    Korashy, H.M.2    El-kadi, O.S.3
  • 5
    • 0023179105 scopus 로고
    • Is there increased cerebral sensitivity to benzodiazepines in chronic liver disease?
    • Branch RA. Is there increased cerebral sensitivity to benzodiazepines in chronic liver disease?. Hepatology 1987;7: 772-776.
    • (1987) Hepatology , vol.7 , pp. 772-776
    • Branch, R.A.1
  • 6
    • 0017033747 scopus 로고
    • Intravenous administration of diazepam in patients with chronic liver disease
    • Branch RA, Morgan MH, James J, Read AE. Intravenous administration of diazepam in patients with chronic liver disease. Gut 1976; 17: 975-983.
    • (1976) Gut , vol.17 , pp. 975-983
    • Branch, R.A.1    Morgan, M.H.2    James, J.3    Read, A.E.4
  • 7
    • 0023255595 scopus 로고
    • Mechanism of the excessive sedative response of cirrhotics to benzodiazepines - model experiments with triazolam
    • Bakti G, Fisch HV, Karlaganis G, Minder G, Bircher J. Mechanism of the excessive sedative response of cirrhotics to benzodiazepines - model experiments with triazolam. Hepatology 1987; 7:629-638.
    • (1987) Hepatology , vol.7 , pp. 629-638
    • Bakti, G.1    Fisch, H.V.2    Karlaganis, G.3    Minder, G.4    Bircher, J.5
  • 8
    • 34548829698 scopus 로고    scopus 로고
    • Cholestasis and endogenous opioids - liver disease and endogenous opioid pharmacokinetics
    • Davis M. Cholestasis and endogenous opioids - liver disease and endogenous opioid pharmacokinetics. Clin Pharmacokinet 2007; 46:825-850.
    • (2007) Clin Pharmacokinet , vol.46 , pp. 825-850
    • Davis, M.1
  • 9
    • 0019407817 scopus 로고
    • Influence of hepatic cirrhosis and end-stage renal disease on pharmacokinetics and pharmacodynamics of furosemide
    • Keller E, Hoppe-Seyler G, Mumm R, Schollmeyer P. Influence of hepatic cirrhosis and end-stage renal disease on pharmacokinetics and pharmacodynamics of furosemide. Eur J Clin Pharmacol 1981;20:27-33.
    • (1981) Eur J Clin Pharmacol , vol.20 , pp. 27-33
    • Keller, E.1    Hoppe-Seyler, G.2    Mumm, R.3    Schollmeyer, P.4
  • 11
    • 0022728614 scopus 로고
    • Increased risk of renal dysfunction due to interaction of liver disease and aminoglycosides
    • Moore RD, Smith CR, Lietman PS. Increased risk of renal dysfunction due to interaction of liver disease and aminoglycosides. Am J Med 1986; 80: 1093-1097.
    • (1986) Am J Med , vol.80 , pp. 1093-1097
    • Moore, R.D.1    Smith, C.R.2    Lietman, P.S.3
  • 12
    • 0021352405 scopus 로고    scopus 로고
    • Clive DM, Staff JS. Medical progress in renal syndromes associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 1984; 310: 563-572.
    • Clive DM, Staff JS. Medical progress in renal syndromes associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 1984; 310: 563-572.
  • 13
    • 0032713507 scopus 로고    scopus 로고
    • Effect of liver disease on pharmacokinetics - an update
    • Rodighiero V. Effect of liver disease on pharmacokinetics - an update. Clin Pharmacokinet 1999;37:399-431.
    • (1999) Clin Pharmacokinet , vol.37 , pp. 399-431
    • Rodighiero, V.1
  • 14
    • 0028857915 scopus 로고
    • Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease-an update
    • Morgan DJ, McLean AJ. Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease-an update. Clin Pharmacokinet 1995;29:370-391.
    • (1995) Clin Pharmacokinet , vol.29 , pp. 370-391
    • Morgan, D.J.1    McLean, A.J.2
  • 15
    • 0030814596 scopus 로고    scopus 로고
    • Drug administration in chronic liver disease
    • Westphal JF, Brogard JM. Drug administration in chronic liver disease. Drug Safety 1997;17: 47-73.
    • (1997) Drug Safety , vol.17 , pp. 47-73
    • Westphal, J.F.1    Brogard, J.M.2
  • 16
    • 0032710519 scopus 로고    scopus 로고
    • Antecedent liver disease and drug toxicity
    • Schenker S, Martin RR, Hoyumpa AM. Antecedent liver disease and drug toxicity. J Hepatol 1999; 31: 1098-1105.
    • (1999) J Hepatol , vol.31 , pp. 1098-1105
    • Schenker, S.1    Martin, R.R.2    Hoyumpa, A.M.3
  • 17
    • 57049161412 scopus 로고    scopus 로고
    • Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction
    • Sep 2, Epub ahead of print
    • Varbeek RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 2008; 2008 Sep 2. [Epub ahead of print].
    • (2008) Eur J Clin Pharmacol
    • Varbeek, R.K.1
  • 18
    • 67651139396 scopus 로고    scopus 로고
    • Guidance for industry: Pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labelling
    • FDA. Guidance for industry: pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labelling. 2003http://www.fda.gov/cber/gdlns/imphep.pdf.
    • 2003http


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.